Molecular Signaling Pathways in Pancreatic Cancer

  • Genevieve M. Boland
  • Sarah P. Thayer
Part of the M. D. Anderson Solid Tumor Oncology Series book series (MDA)

The pancreas is an extremely intriguing organ that has been the topic of discussion and study since its first description by the Greek anatomist and surgeon Herophilus around 300 BC. It is a retroperitoneal gland involved in various processes of human physiology, including blood glucose homeostasis, and secretion of digestive enzymes. In the context of the field of oncology, cancers of the pancreas can be divided into those of exocrine and those of endocrine lineages. The most common tumor of the pancreas is pancreatic adenocarcinoma, responsible for an estimated 37,680 newly diagnosed cases in 2008 with an associated 34,290 deaths from the disease in the same year ( These numbers are a staggering example of the poor prognosis associated with this disease.


Pancreatic Cancer Hepatocyte Growth Factor Notch Signaling Pancreatic Cancer Cell Pancreatic Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Frazier ML.1999, Gene expression in pancreatic adenocarcinoma. Ann N Y Acad Sci 880:1–4.PubMedGoogle Scholar
  2. 2.
    Bardeesy N, DePinho RA. 2002, Pancreatic cancer biology and genetics. Nat Rev Cancer 2:897–909.PubMedGoogle Scholar
  3. 3.
    Yeo TP, Hruban RH, Leach SD, et al. 2002, Pancreatic cancer. Curr Probl Cancer 26:176–275.PubMedGoogle Scholar
  4. 4.
    Iacobuzio-Donahue CA, Hruban RH. 2003, Gene expression in neoplasms of the pancreas: applications to diagnostic pathology. Adv Anat Pathol 10:125–134.PubMedGoogle Scholar
  5. 5.
    Hruban RH, Wilentz RE, Maitra A. 2005, I dentification and analysis of precursors to invasive pancreatic cancer. Methods Mol Med 103:1–13.PubMedGoogle Scholar
  6. 6.
    Hezel AF, Kimmelman AC, Stanger BZ, et al. 2006, Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20:1218–1249.PubMedGoogle Scholar
  7. 7.
    Feldmann G, Beaty R, Hruban RH, et al. 2007, Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 14:224–232.PubMedGoogle Scholar
  8. 8.
    Menke A, Adler G. 2002, TGFbeta-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer 31:41–46.PubMedGoogle Scholar
  9. 9.
    Ellenrieder V, Schneiderhan W, Bachem M, et al. 2004, Fibrogenesis in the pancreas. Rocz Akad Med Bialymst 49:40–46.PubMedGoogle Scholar
  10. 10.
    Jaster R. 2004, Molecular regulation of pancreatic stellate cell function. Mol Cancer 3:26.PubMedGoogle Scholar
  11. 11.
    Truty MJ, Urrutia R. 2007, Transforming growth factor-beta: what every pancreatic surgeon should know. Surgery 141:1–6.PubMedGoogle Scholar
  12. 12.
    Yeo CJ, Cameron JL. 1996, Pancreatic nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5:145–157.PubMedGoogle Scholar
  13. 13.
    Hermanek P. 1998, Pathology and biology of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 383:116–120.PubMedGoogle Scholar
  14. 14.
    Hirai I, Kimura W, Ozawa K, et al. 2002, Perineural invasion in pancreatic cancer. Pancreas 24:15–25.PubMedGoogle Scholar
  15. 15.
    Nakao A, Fujii T, Sugimoto H, et al. 2006, Oncological problems in pancreatic cancer surgery. World J Gastroenterol 12:4466–4472.PubMedGoogle Scholar
  16. 16.
    Berlin JD. 2007, Adjuvant therapy for pancreatic cancer: to treat or not to treat? Oncology (Williston Park) 21:712–718, discussion 20, 25-26, 30.Google Scholar
  17. 17.
    Mulcahy MF. 2007, Adjuvant therapy for pancreas cancer: advances and controversies. Semin Oncol 34:321–326.PubMedGoogle Scholar
  18. 18.
    Hruban RH, Adsay NV, Albores-Saavedra J, et al. 2001, Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579–586.PubMedGoogle Scholar
  19. 19.
    Kloppel G, Luttges J. 2001, WHO-classification 2000: exocrine pancreatic tumors. Verh Dtsch Ges Pathol 85:219–228.PubMedGoogle Scholar
  20. 20.
    Klein WM, Hruban RH, Klein-Szanto AJ, et al. 2002, Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 15:441–447.PubMedGoogle Scholar
  21. 21.
    Biankin AV, Kench JG, Dijkman FP, et al. 2003, Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology 35:14–24.PubMedGoogle Scholar
  22. 22.
    Adsay NV, Basturk O, Cheng JD, et al. 2005, Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol 15:254–264.PubMedGoogle Scholar
  23. 23.
    Laghi L, Orbetegli O, Bianchi P, et al. 2002, Common occurrence of multiple K-RAS muta-tions in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene 21:4301–4306.PubMedGoogle Scholar
  24. 24.
    Hingorani SR, Petricoin EF, Maitra A, et al. 2003, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437–450.PubMedGoogle Scholar
  25. 25.
    Lohr M, Kloppel G, Maisonneuve P, et al. 2005, Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancrea-titis: a meta-analysis. Neoplasia 7:17–23.PubMedGoogle Scholar
  26. 26.
    Heek NT, van Meeker AK, Kern SE, et al. 2002, Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161:1541–1547.PubMedGoogle Scholar
  27. 27.
    Hermanova M, Lukas Z, Nenutil R, et al. 2004, Amplification and overexpression of HER-2/ neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1). Neoplasma 51:77–83.PubMedGoogle Scholar
  28. 28.
    Hustinx SR, Leoni LM, Yeo CJ, et al. 2005, Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a non-invasive precursor lesion. Mod Pathol 18:959–963.PubMedGoogle Scholar
  29. 29.
    Qian J, Niu J, Li M, et al. 2005, In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 65:5045–5053.PubMedGoogle Scholar
  30. 30.
    Abe K, Suda K, Arakawa A, et al. 2007, Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia. Pancreas 34:85–91.PubMedGoogle Scholar
  31. 31.
    Maitra A, Hruban RH. 2005, A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell 8:171–172.PubMedGoogle Scholar
  32. 32.
    Stanger BZ, Dor Y. 2006, Dissecting the cellular origins of pancreatic cancer. Cell Cycle 5:43–46.PubMedGoogle Scholar
  33. 33.
    Friess H, Yamanaka Y, Buchler M, et al. 1993, Enhanced expression of the type II transform-ing growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 53:2704–2707.PubMedGoogle Scholar
  34. 34.
    Chaudhry A, Oberg K, Gobl A, et al. 1994, Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 14:2085–2091.PubMedGoogle Scholar
  35. 35.
    Di Renzo MF, Poulsom R, Olivero M, et al.1995, Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55:1129–1138.PubMedGoogle Scholar
  36. 36.
    Furukawa T, Duguid WP, Kobari M, et al. 1995, Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol 147:889–895.PubMedGoogle Scholar
  37. 38.
    Liu N, Furukawa T, Kobari M, et al. 1998, Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol 153:263–269.PubMedGoogle Scholar
  38. 39.
    Venkatasubbarao K, Ahmed MM, Mohiuddin M, et al. 2000, Differential expression of trans-forming growth factor beta receptors in human pancreatic adenocarcinoma. Anticancer Res 20:43–51.PubMedGoogle Scholar
  39. 40.
    Zhang L, Yuan SZ. 2002, Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 1:620–623.PubMedGoogle Scholar
  40. 41.
    Nio Y, Omori H, Hashimoto K, et al. 2005, I mmunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas. Anticancer Res 25:3523–3529.PubMedGoogle Scholar
  41. 42.
    Ijichi H, Chytil A, Gorska AE, et al. 2006, Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20:3147–3160.PubMedGoogle Scholar
  42. 43.
    Winter JP, de Roelen BA, ten Dijke P, et al. 1997, DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14:1891–1899.PubMedGoogle Scholar
  43. 44.
    Goggins M, Shekher M, Turnacioglu K, et al. 1998, Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58:5329–5332.PubMedGoogle Scholar
  44. 45.
    Dai JL, Schutte M, Bansal RK, et al. 1999, Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol Carcinog 26:37–43.PubMedGoogle Scholar
  45. 46.
    Izeradjene K, Combs C, Best M, et al. 2007, Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11:229–243.PubMedGoogle Scholar
  46. 47.
    Cowgill SM, Muscarella P. 2003, The genetics of pancreatic cancer. Am J Surg 186:279–286.PubMedGoogle Scholar
  47. 48.
    Schneider G, Schmid RM. 2003, Genetic alterations in pancreatic carcinoma. Mol Cancer 2:15.PubMedGoogle Scholar
  48. 49.
    Friedenson B. 2005, BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7:60.PubMedGoogle Scholar
  49. 50.
    Soto JL, Barbera VM, Saceda M, et al. 2006, Molecular biology of exocrine pancreatic cancer. Clin Transl Oncol 8:306–312.PubMedGoogle Scholar
  50. 51.
    Stanger BZ, Stiles B, Lauwers GY, et al. 2005, Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8:185–195.PubMedGoogle Scholar
  51. 52.
    Ohuchida K, Mizumoto K, Murakami M, et al. 2004, Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 64:3215–3222.PubMedGoogle Scholar
  52. 53.
    Micke P, Ostman A. 2005, Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9:1217–1233.PubMedGoogle Scholar
  53. 54.
    Haraguchi N, Utsunomiya T, Inoue H, et al. 2006, Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24:506–513.PubMedGoogle Scholar
  54. 55.
    Lou H, Dean M. 2007, Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26:1357–1360.PubMedGoogle Scholar
  55. 56.
    Neuzil J, Stantic M, Zobalova R, et al. 2007, Tumour-initiating cells vs. cancer ‘ stem’ cells and CD133: what’s in the name? Biochem Biophys Res Commun 355:855–859.PubMedGoogle Scholar
  56. 57.
    Cullingworth J, Hooper ML, Harrison DJ, et al. 2002, Carcinogen-induced pancreatic lesions in the mouse: effect of Smad4 and Apc genotypes. Oncogene 21:4696–4701.PubMedGoogle Scholar
  57. 58.
    Miyamoto Y, Maitra A, Ghosh B, et al. 2003, Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3:565–576.PubMedGoogle Scholar
  58. 59.
    Thayer SP, di Magliano MP, Heiser PW, et al. 2003, Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851–856.PubMedGoogle Scholar
  59. 60.
    Thayer S. 2004, The emerging role of the hedgehog signaling pathway in gastrointestinal cancers. Clin Adv Hematol Oncol 2:17, 20, 63.PubMedGoogle Scholar
  60. 61.
    Dessimoz J, Bonnard C, Huelsken J, et al. 2005, Pancreas-specific deletion of beta-catenin reveals Wnt-dependent and Wnt-independent functions during development. Curr Biol 15:1677–1683.PubMedGoogle Scholar
  61. 62.
    Lee KM, Yasuda H, Hollingsworth MA, et al. 2005, Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest 85:1003–1012.PubMedGoogle Scholar
  62. 63.
    Lewis BC. 2006, Development of the pancreas and pancreatic cancer. Endocrinol Metab Clin North Am 35:397–404, xi.PubMedGoogle Scholar
  63. 64.
    Nakashima H, Nakamura M, Yamaguchi H, et al. 2006, Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic can-cer. Cancer Res 66:7041–7049.PubMedGoogle Scholar
  64. 65.
    Pasca di Magliano M, Sekine S, Ermilov A, et al. 2006, Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 20:3161–3173.PubMedGoogle Scholar
  65. 66.
    Kimura K, Satoh K, Kanno A, et al. 2007, Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci 98:155–162.PubMedGoogle Scholar
  66. 67.
    Liu MS, Yang PY, Yeh TS. 2007, Sonic hedgehog signaling pathway in pancreatic cystic neo-plasms and ductal adenocarcinoma. Pancreas 34:340–346.PubMedGoogle Scholar
  67. 68.
    Morton JP, Mongeau ME, Klimstra DS, et al. 2007, Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A 104:5103–5108.PubMedGoogle Scholar
  68. 69.
    Ripka S, Konig A, Buchholz M, et al. 2007, WNT5A--target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28:1178–1187.PubMedGoogle Scholar
  69. 70. Strobel O, Dor Y, Alsina J, et al. In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 2007, in press.Google Scholar
  70. 71.
    Strobel O, Dor Y, Stirman A, et al. 2007, Beta cell transdifferentiation does not contribute to preneoplastic/metaplastic ductal lesions of the pancreas by genetic lineage tracing in vivo. Proc Natl Acad Sci U S A 104:4419–4424.PubMedGoogle Scholar
  71. 72.
    Potter JD. 2007, Morphogens, morphostats, microarchitecture and malignancy. Nat Rev Cancer 7:464–474.PubMedGoogle Scholar
  72. 73.
    Den Brink GR, Van Bleuming SA, Hardwick JC, et al. 2004, I ndian Hedgehog is an antago-nist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet 36:277–282.Google Scholar
  73. 74.
    Den Brink GR, Van Peppelenbosch MP. 2006, Expression of hedgehog pathway components in the adult colon. Gastroenterology 130:619.PubMedGoogle Scholar
  74. 75.
    Thiery JP. 2003, Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746.PubMedGoogle Scholar
  75. 76.
    Bates RC, Pursell BM, Mercurio AM. 2007, Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells. Cells Tissues Organs 185:29–39.PubMedGoogle Scholar
  76. 77.
    Moustakas A, Heldin CH. 2007, Signaling networks guiding epithelial-mesenchymal transi-tions during embryogenesis and cancer progression. Cancer Sci 98:1512–1520.PubMedGoogle Scholar
  77. 78.
    Bakin AV, Tomlinson AK, Bhowmick NA, et al. 2000, Phosphatidylinositol 3-kinase func-tion is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275:36803–36810.PubMedGoogle Scholar
  78. 79.
    Nakajima S, Doi R, Toyoda E, et al. 2004, N-cadherin expression and epithelial-mesenchy-mal transition in pancreatic carcinoma. Clin Cancer Res 10:4125–4133.PubMedGoogle Scholar
  79. 80.
    Nawshad A, Lagamba D, Polad A, et al. 2005, Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 179:11–23.PubMedGoogle Scholar
  80. 81.
    Gotzmann J, Fischer AN, Zojer M, et al. 2006, A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 25:3170–3185.PubMedGoogle Scholar
  81. 82.
    Yang AD, Camp ER, Fan F, et al. 2006, Vascular endothelial growth factor receptor-1 activa-tion mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66:46–51.PubMedGoogle Scholar
  82. 83.
    Guo Y, Zi X, Koontz Z, et al. 2007, Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloprotein-ases in osteosarcoma Saos-2 cells. J Orthop Res 25:964–971.PubMedGoogle Scholar
  83. 84.
    Kranenburg O. 2005, The KRAS oncogene: past, present, and future. Biochim Biophys Acta 1756:81–82.PubMedGoogle Scholar
  84. 85.
    Cho KN, Lee KI. 2002, Chemistry and biology of Ras farnesyltransferase. Arch Pharm Res 25:759–769.PubMedGoogle Scholar
  85. 86.
    Bos JL. 1989, ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689.PubMedGoogle Scholar
  86. 87.
    Tsukuda K, Tanino M, Soga H, et al. 2000, A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 278:653–658.PubMedGoogle Scholar
  87. 88.
    Hongyo T, Buzard GS, Palli D, et al. 1995, Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 55:2665–2672.PubMedGoogle Scholar
  88. 89.
    Talar-Wojnarowska R, Malecka-Panas E. 2006, Molecular pathogenesis of pancreatic adeno-carcinoma: potential clinical implications. Med Sci Monit 12:RA186–193.PubMedGoogle Scholar
  89. 90.
    Kern S, Hruban R, Hollingsworth MA, et al. 2001, A white paper: the product of a pancreas cancer think tank. Cancer Res 61:4923–4932.PubMedGoogle Scholar
  90. 91.
    Aguirre AJ, Bardeesy N, Sinha M, et al. 2003, Activated Kras and Ink4a/Arf deficiency coop-erate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112–3126.PubMedGoogle Scholar
  91. 92.
    Friess H, Berberat P, Schilling M, et al. 1996, Pancreatic cancer: the potential clinical rele-vance of alterations in growth factors and their receptors. J Mol Med 74:35–42.PubMedGoogle Scholar
  92. 93.
    Campbell PM, Groehler AL, Lee KM, et al. 2007, K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 67:2098–2106.PubMedGoogle Scholar
  93. 94.
    Shields JM, Pruitt K, McFall A, et al. 2000, Understanding Ras: ‘i t ain’t over ‘t il it’s over’ . Trends Cell Biol 10:147–154.PubMedGoogle Scholar
  94. 95.
    Norman KL, Hirasawa K, Yang AD, et al. 2004, Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A 101:11099–11104.PubMedGoogle Scholar
  95. 96.
    Maekawa M, Nishida E, Tanoue T. 2002, Identification of the Anti-proliferative protein Tob as a MAPK substrate. J Biol Chem 277:37783–37787.PubMedGoogle Scholar
  96. 97.
    Hirano T, Shino Y, Saito T, et al. 2002, Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene 21:5923–5928.PubMedGoogle Scholar
  97. 98.
    Xing HR, Campodonico L, Kolesnick R. 2004, The kinase activity of kinase suppressor of Ras1 (KSR1) is independent of bound MEK. J Biol Chem 279:26210–26214.PubMedGoogle Scholar
  98. 99.
    Xing HR, Cordon-Cardo C, Deng X, et al. 2003, Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med 9:1266–1268.PubMedGoogle Scholar
  99. 100.
    Dillon RL, White DE, Muller WJ. 2007, The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26:1338–1345.PubMedGoogle Scholar
  100. 101.
    Song G, Ouyang G, Bao S. 2005, The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59–71.PubMedGoogle Scholar
  101. 102.
    Samuels Y, Ericson K. 2006, Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77–82.PubMedGoogle Scholar
  102. 103.
    Vivanco I, Sawyers CL. 2002, The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501.PubMedGoogle Scholar
  103. 104.
    Schonleben F, Qiu W, Ciau NT, et al. 2006, PIK3CA mutations in intraductal papillary muci-nous neoplasm/carcinoma of the pancreas. Clin Cancer Res 12:3851–3855.PubMedGoogle Scholar
  104. 105.
    Der CJ, Dyke T. Van 2007, Stopping ras in its tracks. Cell 129:855–857.PubMedGoogle Scholar
  105. 106.
    Gupta S, Ramjaun AR, Haiko P, et al. 2007, Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129:957–968.PubMedGoogle Scholar
  106. 107.
    Crespo P, Schuebel KE, Ostrom AA, et al. 1997, Phosphotyrosine-dependent activation of Rac - 1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385:169–172.PubMedGoogle Scholar
  107. 108.
    Takai Y, Sasaki T, Matozaki T. 2001, Small GTP-binding proteins. Physiol Rev 81:153–208.PubMedGoogle Scholar
  108. 109.
    Rodriguez-Viciana P, Warne PH, Khwaja A, et al. 1997, Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467.PubMedGoogle Scholar
  109. 110.
    Crowell JA, Steele VE, Fay JR. 2007, Targeting the AKT protein kinase for cancer chemo-prevention. Mol Cancer Ther 6:2139–2148.PubMedGoogle Scholar
  110. 111.
    Semba S, Moriya T, Kimura W, et al. 2003, Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas 26:250–257.PubMedGoogle Scholar
  111. 112. Parcellier A, Tintignac LA, Zhuravleva E, et al. PKB and the mitochondria: AKTing on apoptosis. Cell Signal 2007.Google Scholar
  112. 113.
    Yamamoto S, Tomita Y, Hoshida Y, et al. 2004, Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10:2846–2850.PubMedGoogle Scholar
  113. 114.
    Leslie NR, Downes CP. 2002, PTEN: The down side of PI 3-kinase signalling. Cell Signal 14:285–295.PubMedGoogle Scholar
  114. 115.
    Ebert MP, Fei G, Schandl L, et al. 2002, Reduced PTEN expression in the pancreas overex-pressing transforming growth factor-beta 1. Br J Cancer 86:257–262.PubMedGoogle Scholar
  115. 116.
    Asano T, Yao Y, Zhu J, et al. 2004, The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23:8571–8580.PubMedGoogle Scholar
  116. 117.
    Li AG, Piluso LG, Cai X, et al. 2006, Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 23:575–587.PubMedGoogle Scholar
  117. 118.
    Ito D, Fujimoto K, Mori T, et al. 2006, In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. I nt J Cancer 118:2337–2343.Google Scholar
  118. 119.
    Wislez M, Spencer ML, Izzo JG, et al. 2005, Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 65:3226–3235.PubMedGoogle Scholar
  119. 120.
    Friday BB, Adjei AA. 2005, K-ras as a target for cancer therapy. Biochim Biophys Acta 1756:127–144.PubMedGoogle Scholar
  120. 121.
    Bruyn KM, de Rooij J, de Wolthuis RM, et al. 2000, RalGEF2, a pleckstrin homology domain containing guanine nucleotide exchange factor for Ral. J Biol Chem 275:29761–29766.PubMedGoogle Scholar
  121. 122.
    Gonzalez-Garcia A, Pritchard CA, Paterson HF, et al. 2005, RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7:219–226.PubMedGoogle Scholar
  122. 123.
    Hamad NM, Elconin JH, Karnoub AE, et al. 2002, Distinct requirements for Ras oncogene-sis in human versus mouse cells. Genes Dev 16:2045–2057.PubMedGoogle Scholar
  123. 124.
    Lim KH, Baines AT, Fiordalisi JJ, et al. 2005, Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 7:533–545.PubMedGoogle Scholar
  124. 125.
    Ji Z, Mei FC, Xie J, et al. 2007, Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 282:14048–14055.PubMedGoogle Scholar
  125. 126.
    He XC, Yin T, Grindley JC, et al. 2007, PTEN-deficient intestinal stem cells initiate intesti-nal polyposis. Nat Genet 39:189–198.PubMedGoogle Scholar
  126. 127.
    Clevers H. 2006, Wnt/beta-catenin signaling in development and disease. Cell 127:469–480.PubMedGoogle Scholar
  127. 128.
    Liebmann C. 2001, Regulation of MAP kinase activity by peptide receptor signalling path-way: paradigms of multiplicity. Cell Signal 13:777–785.PubMedGoogle Scholar
  128. 129.
    Parise LV, Lee J, Juliano RL. 2000, New aspects of integrin signaling in cancer. Semin Cancer Biol 10:407–414.PubMedGoogle Scholar
  129. 130.
    Kinbara K, Goldfinger LE, Hansen M, et al. 2003, Ras GTPases: integrins, friends or foes. Nat Rev Mol Cell Biol 4:767–776.PubMedGoogle Scholar
  130. 131.
    Hackel PO, Zwick E, Prenzel N, et al. 1999, Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184–189.PubMedGoogle Scholar
  131. 132.
    Heldin CH. 1995, Dimerization of cell surface receptors in signal transduction. Cell 80:213–223.PubMedGoogle Scholar
  132. 133.
    Lemmon MA, Schlessinger J. 1994, Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 19:459–463.PubMedGoogle Scholar
  133. 134.
    Korc M. 1998, Role of growth factors in pancreatic cancer. Surg Oncol Clin North Am 7:25–41.Google Scholar
  134. 135.
    Korc M, Chandrasekar B, Yamanaka Y, et al. 1992, Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352–1360.PubMedGoogle Scholar
  135. 136.
    Zhu Z, Kleeff J, Friess H, et al. 2000, Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 273:1019–1024.PubMedGoogle Scholar
  136. 137. 137. Frolov A, Schuller K, Tzeng CW, et al. ErbB3 expression and dimerization with egfr influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 2007, 6.Google Scholar
  137. 138.
    Yu Y, Rishi AK, Turner JR, et al. 2001, Cloning of a novel EGFR - related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol 280:C1083–1089.PubMedGoogle Scholar
  138. 139.
    Kuang C, Xiao Y, Liu X, et al. 2006, In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc Natl Acad Sci U S A 103:858–1863.Google Scholar
  139. 140.
    Wei D, Le X, Zheng L, et al. 2003, Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319–329.PubMedGoogle Scholar
  140. 141. Sharif S, Ramanathan RK, Potter D, et al. NER2/neu gene amplification by fluorescence in situ hybridization (FISH) in resected pancreatic cancer specimens. In: 2005 Gastrointestinal Cancers Symposium, 2005: ASCO Abstract No. 155, 2005.Google Scholar
  141. 142.
    Buchler P, Reber HA, Buchler MC, et al. 2001, Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (Herceptin). J Gastrointest Surg 5:139–146.PubMedGoogle Scholar
  142. 143.
    Sandgren EP, Luetteke NC, Palmiter RD, et al.1990, Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61:1121–1135.PubMedGoogle Scholar
  143. 144.
    Greten FR, Wagner M, Weber CK, et al. 2001, TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology 1:363–368.PubMedGoogle Scholar
  144. 145.
    Freeman JW, Mattingly CA, Strodel WE. 1995, Increased tumorigenicity in the human pan-creatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. J Cell Physiol 165:155–163.PubMedGoogle Scholar
  145. 146.
    Alberts SR, Schroeder M, Erlichman C, et al. 2004, Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol 22:4944–4950.PubMedGoogle Scholar
  146. 147.
    Brummelkamp TR, Bernards R, Agami R. 2002, Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243–247.PubMedGoogle Scholar
  147. 148.
    Cutsem E, Van Velde H, van de Karasek P, et al. 2004, Phase III trial of gemcitabine plus tipi-farnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438.PubMedGoogle Scholar
  148. 149.
    Gjertsen MK, Buanes T, Rosseland AR, et al. 2001, Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441–450.PubMedGoogle Scholar
  149. 150.
    Wallace JA, Locker G, Nattam S, et al. 2007, 2007 ASCO annual meeting proceedings. J Clin Oncol 25:4608.Google Scholar
  150. 151.
    Rinehart J, Adjei AA, Lorusso PM, et al. 2004, Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancre-atic cancer. J Clin Oncol 22:4456–4462.PubMedGoogle Scholar
  151. 152.
    Gold LI. 1999, The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 10:303–360.PubMedGoogle Scholar
  152. 153.
    Rane SG, Lee JH, Lin HM. 2006, Transforming growth factor-beta pathway: role in pan-creas development and pancreatic disease. Cytokine Growth Factor Rev 17:107–119.PubMedGoogle Scholar
  153. 153a.
    Bardeesy N, Cheng KH, Berger JH, et al. 2006, Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20:3130–3146.PubMedGoogle Scholar
  154. 154.
    Coffey RJ, McCutchen CM, Graves-Deal R, et al.1992, Transforming growth factors and related peptides in gastrointestinal neoplasia. J Cell Biochem Suppl 16G:111–118.PubMedGoogle Scholar
  155. 155.
    Moses HL, Arteaga CL, Alexandrow MG, et al. 1994, TGF beta regulation of cell proliferation. Princess Takamatsu Symp 24:250–263.PubMedGoogle Scholar
  156. 156.
    Sakorafas GH, Tsiotou AG, Tsiotos GG. 2000, Molecular biology of pancreatic cancer, oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 26:29–52.PubMedGoogle Scholar
  157. 157.
    Sun L. 2004, Tumor-suppressive and promoting function of transforming growth factor beta. Front Biosci 9:1925–1935.PubMedGoogle Scholar
  158. 158.
    Zavadil J, Bottinger EP. 2005, TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24:5764–5774.PubMedGoogle Scholar
  159. 159.
    Schniewind B, Groth S, Sebens Muerkoster S, et al. 2007, Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene 26:4850–4862.PubMedGoogle Scholar
  160. 160.
    Siegel PM, Massague J. 2003, Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807–821.PubMedGoogle Scholar
  161. 161.
    Teicher BA. 2001, Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 20:133–143.PubMedGoogle Scholar
  162. 162.
    Bhowmick NA, Moses HL. 2005, Tumor-stroma interactions. Curr Opin Genet Dev 15:97–101.PubMedGoogle Scholar
  163. 163.
    Bardeesy N, Aguirre AJ, Chu GC, et al. 2006, Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103:5947–5952.PubMedGoogle Scholar
  164. 164.
    Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. 2000, Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A 97:9624–9629.PubMedGoogle Scholar
  165. 164a.
    Hua Z, Zhang YC, Hu XM, et al. 2003, Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol 9:2764–2767.PubMedGoogle Scholar
  166. 164b.
    Villanueva A, Garcia C, Paules AB, et al. 1998, Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 17:1969–1978.PubMedGoogle Scholar
  167. 165.
    Schwarte-Waldhoff I, Schmiegel W. 2002, Smad4 transcriptional pathways and angiogen-esis. Int J Gastrointest Cancer 31:47–59.PubMedGoogle Scholar
  168. 166.
    Duda DG, Sunamura M, Lefter LP, et al. 2003, Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 22:6857–6864.PubMedGoogle Scholar
  169. 167.
    Ellenrieder V, Hendler SF, Boeck W, et al. 2001, Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61:4222–4228.PubMedGoogle Scholar
  170. 168.
    Rowland-Goldsmith MA, Maruyama H, Matsuda K, et al. 2002, Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 1:161–167.PubMedGoogle Scholar
  171. 169.
    Stella MC, Comoglio PM. 1999, HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31:1357–1362.PubMedGoogle Scholar
  172. 170.
    Ma PC, Maulik G, Christensen J, et al. 2003, c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22:309–325.PubMedGoogle Scholar
  173. 171.
    Ohnishi T, Daikuhara Y. 2003, Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Biol 48:797–804.PubMedGoogle Scholar
  174. 172.
    Kermorgant S, Parker PJ. 2005, c-Met signalling: spatio-temporal decisions. Cell Cycle 4:352–355.PubMedGoogle Scholar
  175. 173.
    Kemp LE, Mulloy B, Gherardi E. 2006, Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors. Biochem Soc Trans 34:414–417.PubMedGoogle Scholar
  176. 174.
    Peruzzi B, Bottaro DP. 2006, Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:3657–3660.PubMedGoogle Scholar
  177. 175.
    Birchmeier W, Brinkmann V, Niemann C, et al. 1997, Role of HGF/SF and c-Met in morpho-genesis and metastasis of epithelial cells. Ciba Found Symp 212:230–240, discussion 40 - 46.PubMedGoogle Scholar
  178. 176.
    Perugini RA, McDade TP, Vittimberga FJ Jr, et al.1998, The molecular and cellular biology of pancreatic cancer. Crit Rev Eukaryot Gene Expr 8:377–393.PubMedGoogle Scholar
  179. 177.
    Otte JM, Kiehne K, Schmitz F, et al. 2000, C-met protooncogene expression and its regulation by cytokines in the regenerating pancreas and in pancreatic cancer cells. Scand J Gastroenterol 35:90–95.PubMedGoogle Scholar
  180. 178.
    Tomioka D, Maehara N, Kuba K, et al. 2001, I nhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61:7518–7524.PubMedGoogle Scholar
  181. 179.
    Betsholtz C. 2004, Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15:215–228.PubMedGoogle Scholar
  182. 180.
    Jones AV, Cross NC. 2004, Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 61:2912–2923.PubMedGoogle Scholar
  183. 181.
    Ostman A. 2004, PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15:275–286.PubMedGoogle Scholar
  184. 182.
    Hwang RF, Yokoi K, Bucana CD, et al. 2003, I nhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9:6534–6544.PubMedGoogle Scholar
  185. 183.
    Zucker S, Cao J, Chen W-T. 2000, Critical appraisal of the use of matrix metalloproteinare inhibitors in Cancer treatment. Oncogene 19:6642–6650.PubMedGoogle Scholar
  186. 184.
    Brantjes H, Barker N, Es J, van et al. 2002, TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol Chem 383:255–261.PubMedGoogle Scholar
  187. 185.
    Reya T, Clevers H. 2005, Wnt signalling in stem cells and cancer. Nature 434:843–850.PubMedGoogle Scholar
  188. 186.
    Giles RH, Es JH, van Clevers H. 2003, Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653:1–24.PubMedGoogle Scholar
  189. 187.
    Crosnier C, Stamataki D, Lewis J. 2006, Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 7:349–359.PubMedGoogle Scholar
  190. 188.
    Wells JM, Esni F, Boivin GP, et al. 2007, Wnt/beta-catenin signaling is required for development of the exocrine pancreas. BMC Dev Biol 7:4.PubMedGoogle Scholar
  191. 189.
    Murtaugh LC, Law AC, Dor Y, et al. 2005, Beta-catenin is essential for pancreatic acinar but not islet development. Development 132:4663–4674.PubMedGoogle Scholar
  192. 190.
    Rulifson IC, Karnik SK, Heiser PW, et al. 2007, Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A 104:6247–6252.PubMedGoogle Scholar
  193. 191.
    Al-Aynati MM, Radulovich N, Riddell RH, et al. 2004, Epithelial-cadherin and beta-catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res 10:1235–1240.PubMedGoogle Scholar
  194. 192.
    Zeng G, Germinaro M, Micsenyi A, et al. 2006, Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8:279–289.PubMedGoogle Scholar
  195. 193.
    Pandur P, Maurus D, Kuhl M. 2002, Increasingly complex: new players enter the Wnt signal-ing network. Bioessays 24:881–884.PubMedGoogle Scholar
  196. 194.
    Katoh M. 2005, WNT/PCP signaling pathway and human cancer (review). Oncol Rep 14:1583–1588.PubMedGoogle Scholar
  197. 195.
    Widelitz R. 2005, Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors 23:111–116.PubMedGoogle Scholar
  198. 196.
    Kim HJ, Schleiffarth JR, Jessurun J, et al. 2005, Wnt5 signaling in vertebrate pancreas devel-opment. BMC Biol 3:23.PubMedGoogle Scholar
  199. 197.
    Aleksic T, Bechtel M, Krndija D, et al. 2007, CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation. Oncogene 26:5939–5949.PubMedGoogle Scholar
  200. 198.
    Michl P, Ramjaun AR, Pardo OE, et al. 2005, CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7:521–532.PubMedGoogle Scholar
  201. 199.
    Michl P, Downward J. 2006, CUTL1: a key mediator of TGFbeta-induced tumor invasion. Cell Cycle 5:132–134.PubMedGoogle Scholar
  202. 200.
    Miele L, Golde T, Osborne B. 2006, Notch signaling in cancer. Curr Mol Med 6:905–918.PubMedGoogle Scholar
  203. 201.
    Buchler P, Gazdhar A, Schubert M, et al. 2005, The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg 242:791–800, discussion -1.PubMedGoogle Scholar
  204. 202.
    Hart A, Papadopoulou S, Edlund H. 2003, Fgf10 maintains notch activation, stimulates pro-liferation, and blocks differentiation of pancreatic epithelial cells. Dev Dyn 228:185–193.PubMedGoogle Scholar
  205. 203.
    Norgaard GA, Jensen JN, Jensen J. 2003, FGF10 signaling maintains the pancreatic progenitor cell state revealing a novel role of Notch in organ development. Dev Biol 264:323–338.PubMedGoogle Scholar
  206. 204.
    Wang Z, Zhang Y, Li Y, et al. 2006, Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5:483–493.PubMedGoogle Scholar
  207. 205.
    Wang Z, Banerjee S, Li Y, et al. 2006, Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metallopro-teinase-9 in pancreatic cancer cells. Cancer Res 66:2778–2784.PubMedGoogle Scholar
  208. 206.
    Wang Z, Sengupta R, Banerjee S, et al. 2006, Epidermal growth factor receptor -related pro-tein inhibits cell growth and invasion in pancreatic cancer. Cancer Res 66:7653–7660.PubMedGoogle Scholar
  209. 207.
    Aramata S, Han SI, Yasuda K, et al. 2005, Synergistic activation of the insulin gene promoter by the beta-cell enriched transcription factors MafA, Beta2, and Pdx1. Biochim Biophys Acta 1730:41–46.PubMedGoogle Scholar
  210. 208.
    Babu DA, Deering TG, Mirmira RG. 2007, A feat of metabolic proportions: Pdx1 orches-trates islet development and function in the maintenance of glucose homeostasis. Mol Genet Metab 92:43–55.PubMedGoogle Scholar
  211. 209.
    Hale MA, Kagami H, Shi L, et al. 2005, The homeodomain protein PDX1 is required at mid -pancreatic development for the formation of the exocrine pancreas. Dev Biol 286:225–237.PubMedGoogle Scholar
  212. 210.
    Johnson JD, Ahmed NT, Luciani DS, et al. 2003, Increased islet apoptosis in Pdx1+/ - mice. J Clin Invest 111:1147–1160.PubMedGoogle Scholar
  213. 211.
    Zhou Q, Law AC, Rajagopal J, et al. 2007, A multipotent progenitor domain guides pancre-atic organogenesis. Dev Cell 13:103–114.PubMedGoogle Scholar
  214. 212.
    Guerra C, Schuhmacher AJ, Canamero M, et al. 2007, Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291–302.PubMedGoogle Scholar
  215. 213.
    Koizumi M, Doi R, Toyoda E, et al. 2003, Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 134:260–266.PubMedGoogle Scholar
  216. 214.
    Okamoto A, Demetrick DJ, Spillare EA, et al.1994, Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A 91:11045–11049.PubMedGoogle Scholar
  217. 215.
    Attri J, Srinivasan R, Majumdar S, et al. 2005, Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. BMC Gastroenterol 5:22.PubMedGoogle Scholar
  218. 216.
    Goldstein AM, Fraser MC, Struewing JP, et al. 1995, Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970–974.PubMedGoogle Scholar
  219. 217.
    Hu YX, Watanabe H, Ohtsubo K, et al. 1997, Frequent loss of p16 expression and its cor-relation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 3:1473–1477.PubMedGoogle Scholar
  220. 218.
    Gerdes B, Ramaswamy A, Ziegler A, et al. 2002, p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg 235:51–59.PubMedGoogle Scholar
  221. 219.
    vos tot Nederveen Cappel WH, de Offerhaus GJ, et al. 2003, Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden). Clin Cancer Res 9:3598–3605.Google Scholar
  222. 220.
    Ohtsubo K, Watanabe H, Yamaguchi Y, et al. 2003, Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol 38:663–671.PubMedGoogle Scholar
  223. 221.
    Rosty C, Geradts J, Sato N, et al. 2003, p16 Inactivation in pancreatic intraepithelial neopla-sias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol 27:1495–1501.PubMedGoogle Scholar
  224. 222.
    Kim WY, Sharpless NE. 2006, The regulation of INK4/ARF in cancer and aging. Cell 127:265–275.PubMedGoogle Scholar
  225. 223.
    Serrano M, Lee H, Chin L, et al. 1996, Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27–37.PubMedGoogle Scholar
  226. 224.
    Sharpless NE, Bardeesy N, Lee KH, et al. 2001, Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413:86–91.PubMedGoogle Scholar
  227. 225.
    Sharpless NE, Ramsey MR, Balasubramanian P, et al. 2004, The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 23:379–385.PubMedGoogle Scholar
  228. 226.
    Whelan AJ, Bartsch D, Goodfellow PJ. 1995, Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333:975–977.PubMedGoogle Scholar
  229. 227.
    Rizos H, Scurr LL, Irvine M, et al. 2007, p14ARF regulates E2F-1 ubiquitination and degra-dation via a p53-dependent mechanism. Cell Cycle 6:1741–1747.PubMedGoogle Scholar
  230. 228.
    Bardeesy N, Morgan J, Sinha M, et al. 2002, Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol 22:635–643.PubMedGoogle Scholar
  231. 229.
    Gartel AL, Serfas MS, Tyner AL. 1996, p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213:138–149.PubMedGoogle Scholar
  232. 230.
    O’Connor PM. 1997, Mammalian G1 and G2 phase checkpoints. Cancer Surv 29:151–182.PubMedGoogle Scholar
  233. 231.
    Winters ZE. 2002, P53 pathways involving G2 checkpoint regulators and the role of their subcellular localisation. J R Coll Surg Edinb 47:591–598.PubMedGoogle Scholar
  234. 232.
    Maddika S, Ande SR, Panigrahi S, et al. 2007, Cell survival, cell death and cell cycle path-ways are interconnected: implications for cancer therapy. Drug Resist Updat 10:13–29.PubMedGoogle Scholar
  235. 234.
    Dotto GP. 2000, p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 1471:M43–56.PubMedGoogle Scholar
  236. 235.
    Paunesku T, Mittal S, Protic M, et al. 2001, Proliferating cell nuclear antigen (PCNA): ring-master of the genome. Int J Radiat Biol 77:1007–1021.PubMedGoogle Scholar
  237. 236.
    Bokoch GM. 1998, Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction. Cell Death Differ 5:637–645.PubMedGoogle Scholar
  238. 237.
    Roig J, Traugh JA. 2001, Cytostatic p21 G protein- activated protein kinase gamma-PAK. Vitam Horm 62:167–198.PubMedGoogle Scholar
  239. 233.
    Biankin AV, Kench JG, Morey AL, et al. 2001, Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 61:8830–8837.PubMedGoogle Scholar
  240. 234.
    Hermanova M, Lukas Z, Kroupova I, et al. 2003, Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma. Neoplasma 50:319–325.PubMedGoogle Scholar
  241. 235.
    Vousden KH, Lu X. 2002, Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604.PubMedGoogle Scholar
  242. 236.
    Moskaluk CA, Hruban RH, Kern SE. 1997, p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140–2143.PubMedGoogle Scholar
  243. 237.
    Chu TM. 1997, Molecular diagnosis of pancreas carcinoma. J Clin Lab Anal 11:225–231.PubMedGoogle Scholar
  244. 238.
    Stewart SA, Weinberg RA. 2006, Telomeres: cancer to human aging. Annu Rev Cell Dev Biol 22:531–557.PubMedGoogle Scholar
  245. 239.
    Moon IK, Jarstfer MB. 2007, The human telomere and its relationship to human disease, therapy, and tissue engineering. Front Biosci 12:4595–4620.PubMedGoogle Scholar
  246. 240.
    Gisselsson D, Hoglund M. 2005, Connecting mitotic instability and chromosome aberrations in cancer - - can telomeres bridge the gap? Semin Cancer Biol 15:13–23.PubMedGoogle Scholar
  247. 241.
    Gisselsson D, Jonson T, Petersen A, et al. 2001, Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malig-nant tumors. Proc Natl Acad Sci U S A 98:12683–12688.PubMedGoogle Scholar
  248. 242.
    Desmaze C, Soria JC, Freulet-Marriere MA, et al. 2003, Telomere-driven genomic instability in cancer cells. Cancer Lett 194:173–182.PubMedGoogle Scholar
  249. 243.
    Mathieu N, Pirzio L, Freulet-Marriere MA, et al. 2004, Telomeres and chromosomal instabil-ity. C ell Mol Life Sci 61:641–656.Google Scholar
  250. 244.
    Rudolph KL, Millard M, Bosenberg MW, et al. 2001, Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28:155–159.PubMedGoogle Scholar
  251. 245.
    Bernhardt SL, Gjertsen MK, Trachsel S, et al. 2006, Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 95:1474–1482.PubMedGoogle Scholar
  252. 246.
    Tahara H, Yasui W, Tahara E, et al. 1999, Immuno-histochemical detection of human telom-erase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18:1561–1567.PubMedGoogle Scholar
  253. 247.
    Suehara N, Mizumoto K, Muta T, et al. 1997, Telomerase elevation in pancreatic ductal car-cinoma compared to nonmalignant pathological states. Clin Cancer Res 3:993–998.PubMedGoogle Scholar
  254. 248.
    Orelli BJ, Bishop DK. 2001, BRCA2 and homologous recombination. Breast Cancer Res 3:294–298.PubMedGoogle Scholar
  255. 249.
    Naderi A, Couch FJ. 2002, BRCA2 and pancreatic cancer. Int J Gastrointest Cancer 31:99–106.PubMedGoogle Scholar
  256. 250.
    Jhanwar-Uniyal M. 2003, BRCA1 in cancer, cell cycle and genomic stability. Front Biosci 8:s1107–1117.PubMedGoogle Scholar
  257. 251.
    Goggins M, Schutte M, Lu J, et al. 1996, Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360–5364.PubMedGoogle Scholar
  258. 252.
    Greer JB, Whitcomb DC. 2007, Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut 56:601–605.PubMedGoogle Scholar
  259. 253.
    Goggins M, Hruban RH, Kern SE. 2000, BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 156:1767–1771.PubMedGoogle Scholar
  260. 254.
    Hartman AR, Ford JM. 2003, BRCA1 and p53: compensatory roles in DNA repair. J Mol Med 81:700–707.PubMedGoogle Scholar
  261. 255.
    Bloomston M, Frankel WL, Petrocca F, et al. 2007, MicroRNA expression patterns to differntiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297:1901–1908.PubMedGoogle Scholar
  262. 256.
    Szafranska AE, Davison TS, John J, et al. 2007, MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26:4442–4452.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Genevieve M. Boland
    • 1
  • Sarah P. Thayer
    • 1
  1. 1.Department of SurgeryMassachusetts General HospitalBostonUSA

Personalised recommendations